AU2006294662A1 - Estriol therapy for autoimmune and neurodegenerataive diseases and disorders - Google Patents

Estriol therapy for autoimmune and neurodegenerataive diseases and disorders Download PDF

Info

Publication number
AU2006294662A1
AU2006294662A1 AU2006294662A AU2006294662A AU2006294662A1 AU 2006294662 A1 AU2006294662 A1 AU 2006294662A1 AU 2006294662 A AU2006294662 A AU 2006294662A AU 2006294662 A AU2006294662 A AU 2006294662A AU 2006294662 A1 AU2006294662 A1 AU 2006294662A1
Authority
AU
Australia
Prior art keywords
treatment
mice
eae
estriol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006294662A
Other languages
English (en)
Inventor
Rhonda R. Voskuhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2006294662A1 publication Critical patent/AU2006294662A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2006294662A 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerataive diseases and disorders Abandoned AU2006294662A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72097205P 2005-09-26 2005-09-26
US60/720,972 2005-09-26
US83352706P 2006-07-26 2006-07-26
US60/833,527 2006-07-26
PCT/US2006/037752 WO2007038636A2 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerataive diseases and disorders

Publications (1)

Publication Number Publication Date
AU2006294662A1 true AU2006294662A1 (en) 2007-04-05

Family

ID=37900442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006294662A Abandoned AU2006294662A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerataive diseases and disorders

Country Status (5)

Country Link
EP (3) EP1929291A4 (enExample)
JP (1) JP2009510084A (enExample)
AU (1) AU2006294662A1 (enExample)
CA (1) CA2623839C (enExample)
WO (1) WO2007038636A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
WO2010050916A1 (en) * 2008-10-31 2010-05-06 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
JP2009510070A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法
EP2164498A4 (en) * 2007-06-04 2010-09-08 Univ California PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US20100239528A1 (en) * 2007-07-20 2010-09-23 Stem Cell Therapeutics Corp. Treating or Ameliorating a Neuroinflammatory or Demyelinating Disorder with Prolactin and Interferon-Beta
CA2700210C (en) 2007-10-26 2015-12-22 Acadia Pharmaceuticals Inc. Condensed compounds with activity at estrogen receptors
HUP0800414A2 (en) * 2008-07-04 2010-10-28 Pecsi Tudomanyegyetem Pharmaceutical combination
EP2688571A1 (en) 2011-03-22 2014-01-29 The Population Council, Inc. Myelin regeneration with androgens
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
WO2015168000A1 (en) 2014-04-28 2015-11-05 The Regents Of The University Of California Estrogen combination for treatment of multiple sclerosis
WO2015168002A1 (en) 2014-04-28 2015-11-05 The Regents Of The University Of California Pharmaceutical packaging for estriol therapy
EP3163284A4 (en) * 2014-06-27 2017-06-28 National University Corporation Nagoya University Embedding medium for specimen preparation, method for preparing curable base material non-penetrating specimen, method for preparing curable base material penetrating specimen, curable base material non-penetrating specimen, thin-slice-performance improver for frozen embedding medium, and frozen embedding medium
WO2016036719A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
EP3189026B1 (en) * 2014-09-02 2020-07-22 The Regents of The University of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2016053946A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions and methods for maintaining cognitive function
WO2016160832A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of monitoring estriol therapy
AU2017322332A1 (en) * 2016-09-12 2019-04-04 Steven Hoffman Compositions for treating dementia
EP3541279B1 (en) * 2016-11-15 2023-09-06 The Regents of the University of California Apparatuses for improving peripheral nerve function
EP3787633A1 (en) 2018-05-02 2021-03-10 Pantarhei Oncology B.V. Treatment of advanced estrogen receptor positive breast cancer
TW202124418A (zh) * 2019-12-20 2021-07-01 比利時商埃斯特拉有限責任公司 壞死性凋亡調節劑、篩選方法及醫藥組成物
CN113243332B (zh) * 2020-02-07 2023-07-28 上海市东方医院（同济大学附属东方医院） 一种广泛脑区神经元树突发育障碍动物模型的制备与应用
US12186564B2 (en) 2021-02-09 2025-01-07 The Regents Of The University Of California Methods and apparatuses for treating stroke using low-frequency stimulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
SE9502921D0 (sv) 1995-08-23 1995-08-23 Astra Ab New compounds
US6734211B1 (en) * 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
AR027878A1 (es) * 1999-11-05 2003-04-16 Wyeth Corp Metodos para identificar y utilizar compuestos inhibidores de amiloides
US6265147B1 (en) * 1999-12-01 2001-07-24 The Board Of Trustees Of The Leland Stanford Junior University Method of screening for neuroprotective agents
AU2002237126A1 (en) * 2001-03-02 2002-09-19 Stem Cell Therapeutics Inc. Use of ovarian hormone for increasing neural stem cell number
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20050209208A1 (en) * 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
JP4801868B2 (ja) * 2002-02-25 2011-10-26 晃史 山口 全身性エリテマトーデス発病抑制薬
EP1358881A1 (en) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
JP2009510070A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法

Also Published As

Publication number Publication date
JP2009510084A (ja) 2009-03-12
WO2007038636A3 (en) 2007-12-27
EP3045177A1 (en) 2016-07-20
EP2698167A2 (en) 2014-02-19
EP2698167A3 (en) 2014-03-05
EP1929291A4 (en) 2010-12-22
EP1929291A2 (en) 2008-06-11
CA2623839C (en) 2013-12-17
CA2623839A1 (en) 2007-04-05
WO2007038636A2 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
CA2623839C (en) Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
US8372826B2 (en) Estriol therapy for multiple sclerosis and other autoimmune diseases
US10610535B2 (en) Diarylpropionitrile therapy for treatment of multiple sclerosis
US9452175B2 (en) Pregnancy hormone combination for treatment of autoimmune diseases
US20090131385A1 (en) Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
US20120328566A9 (en) Estrogen receptor ligand treatment for neurodegenerative diseases
US20050209208A1 (en) Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
US20210137943A1 (en) Estrogen combination for treatment of multiple sclerosis
US20110256096A1 (en) Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases
AU2006294826A1 (en) Estriol therapy for autoimmune and neurodegenerative diseases and disorders
JP2005535664A (ja) インターフェロン−α治療に関連した精神病を処置するための方法
US20090297477A1 (en) Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period